Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21049579 | 0.85 | KDM4E (0.33) | ACHEKDM4EAPOBEC3ASMN1; SMN2APOBEC3G | |
| SCHEMBL21049622 | 0.83 | FDPS (0.32) | KDM4EAPOBEC3ASMN1; SMN2APOBEC3GLMNA | |
| SCHEMBL1095619 | 0.80 | FDPS (0.35) | SMN1; SMN2RAB9A | |
| SCHEMBL1331217 | 0.79 | SMN1; SMN2 (0.39) | KDM4EAPOBEC3ASMN1; SMN2APOBEC3GLMNA | |
| SCHEMBL21049572 | 0.79 | MEN1 (0.38) | SMN1; SMN2RAB9A | |
| SCHEMBL21049626 | 0.78 | MEN1 (0.41) | SMN1; SMN2RAB9A | |
| SCHEMBL21049594 | 0.78 | MEN1 (0.41) | SMN1; SMN2RAB9A | |
| SCHEMBL21049629 | 0.78 | MEN1 (0.41) | SMN1; SMN2RAB9A | |
| SCHEMBL22189073 | 0.78 | MEN1 (0.41) | SMN1; SMN2RAB9A | |
| SCHEMBL21049641 | 0.78 | MEN1 (0.41) | SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563050-B | Amide salt compound, catalyst for polyurethane production and method for producing polyurethane resin | 广荣化学株式会社 | 2023-06-02 | — | — | CN | disclosed |
| EP-3604287-B1 | PRODUCTION METHOD FOR AMIDATE COMPOUND | KOEI CHEMICAL CO (JP) | 2022-08-03 | — | — | EP | disclosed |
| EP-3495353-B1 | AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN | KOEI CHEMICAL CO (JP) | 2021-11-17 | — | — | EP | disclosed |
| US-10689478-B2 | Amidate compound, catalyst for polyurethane production, and method for producing polyurethane resin | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| EP-3604287-A1 | PRODUCTION METHOD FOR AMIDATE COMPOUND | Koei Chemical Company, Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20190177464-A1 | AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2019-06-13 | — | — | US | disclosed |
| EP-3495353-A1 | AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN | Koei Chemical Company, Limited (JP) | 2019-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689478-B2 | Amidate compound, catalyst for polyurethane production, and method for producing polyurethane resin | ARG1, NIT2, RER1 | ACHE 3473/4885KDM4E 2519/4885APOBEC3A 569/4885 |
| US-20190177464-A1 | AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN | ARG1, NIT2, RER1 | ACHE 3473/4885KDM4E 2519/4885APOBEC3A 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.